Zeneca Sets Up Foundation in China
Bioscience group Zeneca is helping to establish a medical science foundation in China. The new foundation is to be a joint effort between Zeneca and the State Pharmaceutical Administration of China.
The UK-based company is investing $250,000 in the foundation, which will run an annual competition for young scientists, inventors and researchers. Zeneca Sino-Pharm Development Consulting Company, a joint venture consultancy company (see page 5) will help administer the foundation, which will be named after Sir James Black, a Nobel prizewinner and a former researcher at Zeneca Pharma-ceutical's forerunner, ICI Pharmaceuticals.
"We are delighted to be able to create this foundation named after such an eminent medical scientist as Sir James," said Tom McKillop, chief executive of pharmaceuticals at Zeneca.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze